Cosmetic-Drug Ingredient Review Deferral To CIR Suggested By Attorney
This article was originally published in The Tan Sheet
Executive Summary
FDA should refer the review of cosmetic-drug ingredients to independent Cosmetic Ingredient Review panel rather than spend extended periods developing drug monographs, consultant David Steinberg (Steinberg & Associates) said at a public hearing on OTC drug regulation in Gaithersburg, Md. June 28-29.